The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
Open accessAbstract
Factors associated with hepatitis B virus (HBV) DNA breakthrough and the significance of YMDD variants without the presence of wild-type YMDD during prolonged lamivudine treatment are unknown. We studied the amino acid sequence of codon 552 (YMDD motif) and codon 528 by means of a line probe assay in 159 chronic HBV patients (median follow-up 29.6 months). Pretreatment HBV DNA levels and alanine transaminase (ALT) levels correlated inversely with the time to HBV DNA breakthrough with YMDD variants (r = −0.46, P = .001; r = −0.45, P = .001 respectively). Patients harboring YMDD variants 3 months before HBV DNA breakthroughs had higher HBV DNA breakthrough levels compared with those without YMDD variants 3 months before HBV DNA breakthroughs (18.9 × 10 6 vs. 5.4 × 10 6 copies/mL, P = .007). Patients with HBV DNA breakthroughs had higher percentages of YMDD variants without the presence of wild-type YMDD compared with patients without HBV DNA breakthrough (25.6% vs. 9%, P = .007 for single M552I variant; 20.9% vs. 8.1%, P = .026 for single M552V variant; 30.2% vs. 9.9%, P = .004 for M552I/M552V variants). Patients with HBV DNA levels of more than 10 3 copies/mL after 6 months of lamivudine therapy had a 63.2% chance of subsequently developing YMDD variants. HBeAg seroconversion occurred in 2 patients after the emergence of YMDD variants. Only one patient developed YMDD variant after HBeAg seroconversion. There was no increase in the rate of development of YMDD variants or L528M mutation in patients receiving lamivudine 25 mg daily or famciclovir 500 mg 3 times a day before being given lamivudine 100 mg daily.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Self-citationLAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Allen, M. I., Deslauriers, M., Andrews, W. C., Tipples, G. A., Walters, K.-A., Tyrrell, D. L., Brown, N., & Condreay, L. D. (1998) · Hepatology · doi:10.1002/hep.510270628 · Cited by 793
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 689
Self-citationBenhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., & Poynard, T. (1999) · Hepatology · doi:10.1002/hep.510300525 · Cited by 424
Quantitation of HBV DNA in Human Serum Using a Branched DNA (bDNA) Signal Amplification Assay
Hendricks, D. A., Stowe, B. J., Hoo, B., et al. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.5.537 · Cited by 133
Seignères, B., Pichoud, C., Ahmed, S. S., Hantz, O., TREPO, C. G., & Zoulim, F. (2000) · The Journal of Infectious Diseases · doi:10.1086/315368 · Cited by 72
Profound suppression of hepatitis B virus replication with lamivudine
Lai, C., & Yuen, M. (2000) · Journal of Medical Virology · Cited by 45
Self-citation
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Observational studies assessing the effect of interferon showed a potential effect in reduction of HCC incidence [37], but this was not confirmed by Asian casecontrolled studies [38].”
ResultAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationTelbivudine versus Lamivudine in Patients with Chronic Hepatitis B
Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066422 · Cited by 773
Self-citationMommeja-Marin, H., Mondou, E., Blum, R. M., & Rousseau, F. (2003) · Hepatology · doi:10.1053/jhep.2003.50208 · Cited by 275
Metadata
- Authors
- Yuen, M.-F., Sablon, E., Hui, C.-K., Yuan, H.-J., Decraemer, H., & Lai, C.-L.
- Venue
- Hepatology
- Published
- 2001-10
- Volume
- 34
- Issue
- 4
- Pages
- 785-791
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2009944703
- Cited by
- 386
- References
- 8
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. https://app.cochat.ai/papers/10.1053/jhep.2001.27563
- The paper
- Yuen, M.-F., Sablon, E., Hui, C.-K., Yuan, H.-J., Decraemer, H., & Lai, C.-L. (2001). Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. https://doi.org/10.1053/jhep.2001.27563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
